Tevogen Bio Holdings Inc. (NASDAQ:TVGN) Short Interest Up 127.9% in January

Tevogen Bio Holdings Inc. (NASDAQ:TVGNGet Free Report) was the target of a large growth in short interest in January. As of January 31st, there was short interest totalling 2,780,000 shares, a growth of 127.9% from the January 15th total of 1,220,000 shares. Based on an average daily volume of 3,280,000 shares, the days-to-cover ratio is currently 0.8 days. Approximately 11.2% of the shares of the stock are sold short.

Institutional Inflows and Outflows

A number of institutional investors have recently bought and sold shares of TVGN. China Universal Asset Management Co. Ltd. acquired a new stake in shares of Tevogen Bio during the 4th quarter worth approximately $38,000. JPMorgan Chase & Co. increased its holdings in shares of Tevogen Bio by 74.2% during the 4th quarter. JPMorgan Chase & Co. now owns 39,207 shares of the company’s stock worth $40,000 after buying an additional 16,695 shares during the last quarter. Barclays PLC increased its holdings in shares of Tevogen Bio by 39.2% during the 4th quarter. Barclays PLC now owns 45,600 shares of the company’s stock worth $48,000 after buying an additional 12,847 shares during the last quarter. XTX Topco Ltd acquired a new stake in shares of Tevogen Bio during the 4th quarter worth approximately $55,000. Finally, HGC Investment Management Inc. acquired a new stake in shares of Tevogen Bio during the 3rd quarter worth approximately $82,000.

Tevogen Bio Price Performance

TVGN opened at $1.56 on Friday. The company’s 50 day simple moving average is $1.24 and its two-hundred day simple moving average is $1.07. Tevogen Bio has a 1-year low of $0.26 and a 1-year high of $21.09.

About Tevogen Bio

(Get Free Report)

Tevogen Bio Holdings Inc operates as a clinical-stage specialty immunotherapy company that develops off-the-shelf precision T cell therapies for the treatment of infectious diseases, cancers, and neurological disorders. The company develops TVGN 489, which has completed Phase 1 clinical trial for the treatment and prevention of chronic lingering symptoms of the disease (Long COVID), as well as COVID-19 in B cell immune suppressed acute COVID-19 patients without a B cell cancer indication, elderly and infirm acute COVID-19 patients, and acute COVID-19 in patients on T cell suppressing drugs, including solid organ transplant patients.

Featured Stories

Receive News & Ratings for Tevogen Bio Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Tevogen Bio and related companies with MarketBeat.com's FREE daily email newsletter.